205 related articles for article (PubMed ID: 17032931)
21. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Geerts WH; Pineo GF; Heit JA; Bergqvist D; Lassen MR; Colwell CW; Ray JG
Chest; 2004 Sep; 126(3 Suppl):338S-400S. PubMed ID: 15383478
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity.
Amin A; Kartashov A; Ngai W; Steele K; Rosenthal N
Front Cardiovasc Med; 2023; 10():1163684. PubMed ID: 37396589
[TBL] [Abstract][Full Text] [Related]
23. Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.
Pineo GF; Hull RD
Clin Appl Thromb Hemost; 2009 Oct; 15(5):489-500. PubMed ID: 19520676
[TBL] [Abstract][Full Text] [Related]
24. Impact of thromboprophylaxis across the US acute care setting.
Huang W; Anderson FA; Rushton-Smith SK; Cohen AT
PLoS One; 2015; 10(3):e0121429. PubMed ID: 25816146
[TBL] [Abstract][Full Text] [Related]
25. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
27. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.
Mahan CE; Fisher MD; Mills RM; Fields LE; Stephenson JJ; Fu AC; Spyropoulos AC
Thromb Res; 2013 Nov; 132(5):520-6. PubMed ID: 24080150
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.
Amin AN; Kartashov A; Ngai W; Steele K; Rosenthal N
J Health Econ Outcomes Res; 2024; 11(1):44-56. PubMed ID: 38390025
[No Abstract] [Full Text] [Related]
29. Venous thromboembolic risk and its prevention in hospitalized medical patients.
Haas SK
Semin Thromb Hemost; 2002 Dec; 28(6):577-84. PubMed ID: 12536351
[TBL] [Abstract][Full Text] [Related]
30. Thromboembolism prophylaxis in medical inpatients: effect on outcomes and costs.
Baser O; Sengupta N; Dysinger A; Wang L
Am J Manag Care; 2012 Jun; 18(6):294-302. PubMed ID: 22774997
[TBL] [Abstract][Full Text] [Related]
31. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*.
Lim W; Meade M; Lauzier F; Zarychanski R; Mehta S; Lamontagne F; Dodek P; McIntyre L; Hall R; Heels-Ansdell D; Fowler R; Pai M; Guyatt G; Crowther MA; Warkentin TE; Devereaux PJ; Walter SD; Muscedere J; Herridge M; Turgeon AF; Geerts W; Finfer S; Jacka M; Berwanger O; Ostermann M; Qushmaq I; Friedrich JO; Cook DJ;
Crit Care Med; 2015 Feb; 43(2):401-10. PubMed ID: 25474533
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
[TBL] [Abstract][Full Text] [Related]
33. Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis.
Busch M; Masuhr F
Eur J Med Res; 2004 Apr; 9(4):199-206. PubMed ID: 15210400
[TBL] [Abstract][Full Text] [Related]
34. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
35. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials.
Alhazzani W; Lim W; Jaeschke RZ; Murad MH; Cade J; Cook DJ
Crit Care Med; 2013 Sep; 41(9):2088-98. PubMed ID: 23782973
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials.
Park J; Lee JM; Lee JS; Cho YJ
J Korean Med Sci; 2016 Nov; 31(11):1828-1837. PubMed ID: 27709864
[TBL] [Abstract][Full Text] [Related]
38. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
Shorr AF; Jackson WL; Weiss BM; Moores LK
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin.
Jones TE; Smith BJ; Polasek JF
Expert Opin Pharmacother; 2004 Sep; 5(9):1887-97. PubMed ID: 15330727
[TBL] [Abstract][Full Text] [Related]
40. Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit.
Lauzier F; Muscedere J; Deland E; Kutsogiannis DJ; Jacka M; Heels-Ansdell D; Crowther M; Cartin-Ceba R; Cox MJ; Zytaruk N; Foster D; Sinuff T; Clarke F; Thompson P; Hanna S; Cook D; ;
Crit Care; 2014 Apr; 18(2):R82. PubMed ID: 24766968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
